Skip to content Skip to footer

Going beyond symptoms - Treating mental disorders by using data originating in deep brain regions

Prism will be used by Healthcare Providers to enhance standard of care clinical outcomes.

Prism uses an Amygdala-fMRI-guided model for processing EEG signals. Prism uses several electrodes EEG-signal to produce a real time Amygdala-derived-EFP biomarker signal to train patients in downregulating the Amygdala-derived-EFP biomarker during neurofeedback.

Prism: Supercharging EEG processing with fMRI data

EEG neurofeedback is considered incapable of measuring deep brain regions. Prism is taking a different approach.

Prism’s innovative technology is created in 3 steps:

Step 1

A unique data set of fMRI and EEG



Concurrent EEG and fMRI data was acquired from multiple sessions where the fMRI and EEG were synchronized.


Step 2

Brain area specific EFP (EEG fMRI Pattern)

Using a proprietary model, a unique patient-generic EFP (EEG fMRI pattern) biomarker was created from the synchronized fMRI-EEG data.


Step 3

The Prism system

The EFP model was embedded in Prism forming  an EEG neurofeedback device (no fMRI needed) used to train patients to regulate the EFP biomarker signal. Therapy includes 15 thirty-minute sessions, conducted twice a week for a period of 8 weeks (about 2 months). Prism is designed to fit at any clinic.

PTSD-first, to be followed by an extensive pipeline

Our first-to-market solution, Prism for PTSD, is a promising software as a medical device for the treatment of PTSD as an adjunct to standard of care. About 250 million people worldwide live with PTSD, yet treatments are lacking and often lead to side effects that may last a lifetime.  

Prism for PTSD: An adjunct to standard of care therapy, was validated in a multi-center clinical trial in 5 medical centers in the USA and in Israel. While using Prism, patients learn to downregulate the amygdala-derived-EFP signal and how to control their PTSD symptoms under the supervision of a healthcare provider.

Relevant publications

Prism’s EFP technology has been extensively published in prestigious medical journals, demonstrating significant clinical improvement across multiple indications and no severe side effects, as an adjunct to standard of care.


We are an innovative company that offers real-time treatment by measuring amygdala-derived-EFP biomarkers

GrayMatters is an innovative company that offers real-time treatment by measuring

amygdala-derived-EFP biomarkers

PTSD-first, to be followed by an extensive pipeline

Our first-to-market solution, Prism for PTSD, is a promising software as a medical device for the treatment of PTSD as an adjunct to standard of care. About 250 million people worldwide live with PTSD, yet treatments are lacking and often lead to side effects that may last a lifetime.

Prism for PTSD: An adjunct to standard of care therapy, was validated in a multi-center clinical trial in 5 medical centers in the USA and in Israel. While using Prism, patients learn to downregulate the amygdala-derived-EFP signal and how to control their PTSD symptoms under the supervision of a healthcare provider.

 

Relevant publications

Prism’s EFP technology has been extensively published in prestigious medical journals, demonstrating significant clinical improvement across multiple indications and no severe side effects, as an adjunct to standard of care.

We are an innovative company that offers real-time treatment by measuring amygdala-derived-EFP biomarkers.

Our Team

Prof. Talma Hendler, MD, PhD

Inventor, SAB Chairperson, Chief Medical Scientist

Oded Kraft

co-founder, CEO, President

Rani Cohen

co-founder, Executive chairman, BD

Gary J Sagiv

VP of Business Development and Product Management

Adar Shani

VP Clinical, Regulatory & Quality Affairs

Shai Attia

co-founder, VP R&D

Our Partners

Our Partners

Contact Details

Derech HaAtsma'ut 82Haifa

    Go To Top